XOMAO
Closed
Xoma Corporation
25.4116
-0.0119 (-0.05%)
Last Update: 12 Mar 2025 23:00:00
Yesterday: 25.4235
Day's Range: 25.3447 - 25.4116
Send
sign up or login to leave a comment!
When Written:
24.21
XOMA Corporation is a biotechnology company that develops and commercializes therapeutic antibodies and other biologic medicines. The company was founded in 1981 and is headquartered in Emeryville, California.
XOMA's primary focus is on developing drugs for rare diseases and oncology. The company utilizes its proprietary antibody discovery and development platform, which includes its phage display technology, to identify and develop new drugs.
XOMA has several products in its pipeline, including XOMA 358 for the treatment of hypoglycemia, XOMA 213 for the treatment of hyperinsulinemic hypoglycemia, and XOMA 129 for the treatment of acute pyelonephritis.
The company has partnerships with several pharmaceutical companies, including Novartis, Takeda, and Rezolute, to develop and commercialize its products.
XOMA is publicly traded on the NASDAQ stock exchange under the ticker symbol XOMA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
XOMA's primary focus is on developing drugs for rare diseases and oncology. The company utilizes its proprietary antibody discovery and development platform, which includes its phage display technology, to identify and develop new drugs.
XOMA has several products in its pipeline, including XOMA 358 for the treatment of hypoglycemia, XOMA 213 for the treatment of hyperinsulinemic hypoglycemia, and XOMA 129 for the treatment of acute pyelonephritis.
The company has partnerships with several pharmaceutical companies, including Novartis, Takeda, and Rezolute, to develop and commercialize its products.
XOMA is publicly traded on the NASDAQ stock exchange under the ticker symbol XOMA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
24.21
XOMA Corporation is a biotechnology company that specializes in the discovery, development, and commercialization of therapeutic antibodies. The company was founded in 1981 and is headquartered in Emeryville, California.
XOMA has a number of proprietary technologies and platforms, including its phage display library, which allows for the rapid identification of therapeutic antibodies. The company's pipeline includes a range of programs in various stages of development, including treatments for rare diseases, cancer, and inflammatory conditions.
In addition to its own pipeline, XOMA also partners with other companies to develop and commercialize antibody-based therapies. The company has collaborations with a number of pharmaceutical and biotech companies, including Novartis, Takeda, and Rezolute.
XOMA has a strong financial position, with a cash balance of over $130 million as of 2021. The company has a market capitalization of approximately $228 million as of August 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
XOMA has a number of proprietary technologies and platforms, including its phage display library, which allows for the rapid identification of therapeutic antibodies. The company's pipeline includes a range of programs in various stages of development, including treatments for rare diseases, cancer, and inflammatory conditions.
In addition to its own pipeline, XOMA also partners with other companies to develop and commercialize antibody-based therapies. The company has collaborations with a number of pharmaceutical and biotech companies, including Novartis, Takeda, and Rezolute.
XOMA has a strong financial position, with a cash balance of over $130 million as of 2021. The company has a market capitalization of approximately $228 million as of August 2021.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!